588 related articles for article (PubMed ID: 31129358)
1. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
2. In vivo cancer vaccination: Which dendritic cells to target and how?
Chiang CL; Kandalaft LE
Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptors TLR-2, TLR-4, TLR-7, and TLR-9 in tumor tissue and serum of the patients with esophageal squamous cell carcinoma and gastro-esophageal junction cancer.
Diakowska D; Nienartowicz M; Grabowski K; Rosińczuk J; Krzystek-Korpacka M
Adv Clin Exp Med; 2019 Apr; 28(4):515-522. PubMed ID: 29968427
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptors as adjuvant receptors.
Kaisho T; Akira S
Biochim Biophys Acta; 2002 Feb; 1589(1):1-13. PubMed ID: 11909637
[TBL] [Abstract][Full Text] [Related]
5. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
6. TLR activation pathways in HIV-1-exposed seronegative individuals.
Biasin M; Piacentini L; Lo Caputo S; Naddeo V; Pierotti P; Borelli M; Trabattoni D; Mazzotta F; Shearer GM; Clerici M
J Immunol; 2010 Mar; 184(5):2710-7. PubMed ID: 20124101
[TBL] [Abstract][Full Text] [Related]
7. Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia.
Corthals SL; Wynne K; She K; Shimizu H; Curman D; Garbutt K; Reid GS
Br J Haematol; 2006 Feb; 132(4):452-8. PubMed ID: 16412017
[TBL] [Abstract][Full Text] [Related]
8. Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer.
Hong X; Dong T; Hu J; Yi T; Li W; Zhang Z; Lin S; Niu W
Int J Colorectal Dis; 2013 Jan; 28(1):25-33. PubMed ID: 22777000
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
10. Human toll-like receptor 8 (TLR8) in NK cells: Implication for cancer immunotherapy.
Veneziani I; Alicata C; Moretta L; Maggi E
Immunol Lett; 2023 Sep; 261():13-16. PubMed ID: 37451320
[TBL] [Abstract][Full Text] [Related]
11. Expression and distribution of Toll-like receptors in the brain during murine neurocysticercosis.
Mishra BB; Mishra PK; Teale JM
J Neuroimmunol; 2006 Dec; 181(1-2):46-56. PubMed ID: 17011049
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor (TLR) expression of immune system cells from metastatic breast cancer patients with circulating tumor cells.
Green TL; Santos MF; Ejaeidi AA; Craft BS; Lewis RE; Cruse JM
Exp Mol Pathol; 2014 Aug; 97(1):44-8. PubMed ID: 24836676
[TBL] [Abstract][Full Text] [Related]
13. Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9.
Yu N; Zhang S; Zuo F; Kang K; Guan M; Xiang L
J Dermatol Sci; 2009 Nov; 56(2):113-20. PubMed ID: 19740627
[TBL] [Abstract][Full Text] [Related]
14. TLR expression in human melanoma cells.
Saint-Jean M; Knol AC; Nguyen JM; Khammari A; Dréno B
Eur J Dermatol; 2011; 21(6):899-905. PubMed ID: 21926036
[TBL] [Abstract][Full Text] [Related]
15. Targeting Toll-Like Receptors for Cancer Therapy.
Braunstein MJ; Kucharczyk J; Adams S
Target Oncol; 2018 Oct; 13(5):583-598. PubMed ID: 30229471
[TBL] [Abstract][Full Text] [Related]
16. TLR based therapeutics.
Dunne A; Marshall NA; Mills KH
Curr Opin Pharmacol; 2011 Aug; 11(4):404-11. PubMed ID: 21501972
[TBL] [Abstract][Full Text] [Related]
17. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
Schmitt A; Li L; Giannopoulos K; Greiner J; Reinhardt P; Wiesneth M; Schmitt M
Transfusion; 2008 May; 48(5):861-70. PubMed ID: 18208411
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptors: The role in bladder cancer development, progression and immunotherapy.
Ohadian Moghadam S; Nowroozi MR
Scand J Immunol; 2019 Dec; 90(6):e12818. PubMed ID: 31448424
[TBL] [Abstract][Full Text] [Related]
19. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
Lee SN; Jin SM; Shin HS; Lim YT
Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
[TBL] [Abstract][Full Text] [Related]
20. Regulation of dendritic cell function through Toll-like receptors.
Kaisho T; Akira S
Curr Mol Med; 2003 Jun; 3(4):373-85. PubMed ID: 12776992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
